News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,638 Results
Type
Article (43004)
Company Profile (268)
Press Release (669365)
Multimedia
Podcasts (67)
Webinars (14)
Section
Business (205674)
Career Advice (2061)
Deals (35639)
Drug Delivery (98)
Drug Development (82400)
Employer Resources (172)
FDA (16364)
Job Trends (15049)
News (348382)
Policy (32877)
Tag
Academia (2647)
Accelerated approval (11)
Adcomms (24)
Allergies (96)
Alliances (50144)
ALS (112)
Alzheimer's disease (1475)
Antibody-drug conjugate (ADC) (163)
Approvals (16353)
Artificial intelligence (319)
Autoimmune disease (30)
Automation (19)
Bankruptcy (362)
Best Places to Work (11751)
BIOSECURE Act (20)
Biosimilars (122)
Biotechnology (190)
Bladder cancer (94)
Brain cancer (35)
Breast cancer (370)
Cancer (2918)
Cardiovascular disease (215)
Career advice (1723)
Career pathing (31)
CAR-T (186)
CDC (31)
Cell therapy (510)
Cervical cancer (23)
Clinical research (67711)
Collaboration (1039)
Company closure (3)
Compensation (687)
Complete response letters (25)
COVID-19 (2685)
CRISPR (61)
C-suite (335)
Cystic fibrosis (116)
Data (3026)
Decentralized trials (2)
Denatured (21)
Depression (69)
Diabetes (348)
Diagnostics (6463)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (142)
Drug pricing (124)
Drug shortages (28)
Duchenne muscular dystrophy (128)
Earnings (87634)
Editorial (45)
Employer branding (21)
Employer resources (148)
Events (114627)
Executive appointments (852)
FDA (18036)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (952)
Gene editing (134)
Generative AI (23)
Gene therapy (388)
GLP-1 (821)
Government (4554)
Grass and pollen (4)
Guidances (181)
Healthcare (18998)
HIV (42)
Huntington's disease (30)
IgA nephropathy (40)
Immunology and inflammation (154)
Immuno-oncology (10)
Indications (39)
Infectious disease (2862)
Inflammatory bowel disease (151)
Inflation Reduction Act (10)
Influenza (63)
Intellectual property (121)
Interviews (322)
IPO (16638)
IRA (45)
Job creations (3691)
Job search strategy (1460)
Kidney cancer (13)
Labor market (52)
Layoffs (502)
Leadership (18)
Legal (7995)
Liver cancer (79)
Longevity (11)
Lung cancer (404)
Lymphoma (211)
Machine learning (11)
Management (58)
Manufacturing (397)
MASH (92)
Medical device (13539)
Medtech (13544)
Mergers & acquisitions (19722)
Metabolic disorders (870)
Multiple sclerosis (100)
NASH (17)
Neurodegenerative disease (123)
Neuropsychiatric disorders (36)
Neuroscience (2184)
NextGen: Class of 2025 (6598)
Non-profit (4560)
Now hiring (47)
Obesity (440)
Opinion (230)
Ovarian cancer (103)
Pain (112)
Pancreatic cancer (123)
Parkinson's disease (194)
Partnered (22)
Patents (303)
Patient recruitment (170)
Peanut (50)
People (58114)
Pharmaceutical (66)
Pharmacy benefit managers (21)
Phase I (21153)
Phase II (29855)
Phase III (22151)
Pipeline (1652)
Policy (209)
Postmarket research (2605)
Preclinical (9081)
Press Release (67)
Prostate cancer (143)
Psychedelics (38)
Radiopharmaceuticals (264)
Rare diseases (480)
Real estate (5966)
Recruiting (66)
Regulatory (22818)
Reports (50)
Research institute (2395)
Resumes & cover letters (356)
Rett syndrome (10)
RNA editing (9)
RSV (51)
Schizophrenia (90)
Series A (163)
Series B (113)
Service/supplier (11)
Sickle cell disease (62)
Special edition (20)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3679)
State (2)
Stomach cancer (17)
Supply chain (77)
Tariffs (60)
The Weekly (44)
Vaccines (807)
Venture capital (54)
Weight loss (271)
Women's health (47)
Worklife (16)
Date
Today (90)
Last 7 days (358)
Last 30 days (1859)
Last 365 days (31476)
2025 (16997)
2024 (35577)
2023 (40463)
2022 (51512)
2021 (56105)
2020 (54474)
2019 (46936)
2018 (35375)
2017 (32518)
2016 (31946)
2015 (38003)
2014 (31699)
2013 (26745)
2012 (28963)
2011 (29617)
2010 (27693)
Location
Africa (746)
Alabama (62)
Alaska (7)
Arizona (247)
Arkansas (13)
Asia (38854)
Australia (6380)
California (7474)
Canada (2366)
China (685)
Colorado (322)
Connecticut (321)
Delaware (192)
Europe (84216)
Florida (1122)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (654)
India (27)
Indiana (364)
Iowa (16)
Japan (229)
Kansas (110)
Kentucky (29)
Louisiana (15)
Maine (64)
Maryland (1026)
Massachusetts (5580)
Michigan (246)
Minnesota (456)
Mississippi (3)
Missouri (91)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (67)
New Jersey (2090)
New Mexico (29)
New York (2096)
North Carolina (1083)
North Dakota (8)
Northern California (3287)
Ohio (236)
Oklahoma (16)
Oregon (36)
Pennsylvania (1619)
Puerto Rico (17)
Rhode Island (36)
South America (1122)
South Carolina (34)
South Dakota (1)
Southern California (2791)
Tennessee (127)
Texas (1137)
United States (27754)
Utah (221)
Virginia (186)
Washington D.C. (74)
Washington State (636)
West Virginia (4)
Wisconsin (68)
712,638 Results for "promis neurosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
May 12, 2025
·
14 min read
Press Releases
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
June 17, 2025
·
3 min read
Press Releases
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
March 11, 2025
·
1 min read
Press Releases
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
April 1, 2025
·
14 min read
Press Releases
ProMIS Neurosciences Issues Letter to Shareholders
January 14, 2025
·
9 min read
Press Releases
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
·
1 min read
Business
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Inc. announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 14, 2024
·
10 min read
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
ProMIS Neurosciences, Inc. announced that the European Patent Office, Japanese Patent Office and IP Australia, the Australian patent office, have recently allowed composition of matter and method of use patent applications related to ProMIS Neurosciences’ lead product candidate, PMN310, for the treatment of Alzheimer’s disease .
March 11, 2024
·
5 min read
Business
ProMIS Neurosciences, Inc. Announces Leadership Transition
ProMIS Neurosciences Inc., a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced a strategic leadership change.
January 3, 2024
·
6 min read
Genetown
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
ProMIS Neurosciences Inc. today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.
February 22, 2024
·
1 min read
1 of 71,264
Next
